Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk A/S NVO reported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER).

  • Diabetes and Obesity care sales drove the increased sales as GLP-1 sales increased by 36% at CER. Obesity care sales increased by 73%, partially offset by decreased insulin sales by 1%. Biopharm sales increased by 6% at CER.
  • Novo reported a fourth-quarter operating profit of DKK 13.63 billion, an increase of 16% at CER over the corresponding period last year.
  • Related: FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report.
  • In December, a contract manufacturer halted deliveries and manufacturing temporarily after issues relating to good manufacturing practice.
  • Fewer new weekly patient initiations are expected in 1H of 2022 compared to Q4 FY21. Novo Nordisk still hopes to meet demand in the U.S. in 2H of 2022.
  • Share Buyback: The Board of Directors intends to initiate a new 12-month share repurchase program of up to DKK 22 billion.
  • Guidance: The company expects to generate sales growth of 6% - 10% and deliver operating profit growth of 4% - 8% at CER in 2022.
  • Price Action: NVO shares are up 3.89% at $106.60 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareBuybacksMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!